Actuate 1901: 9-ING-41 in Myelofibrosis

NCT04218071 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

17

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelofibrosis

Interventions

DRUG: Ruxolitinib
DRUG: 9-ING-41

Sponsor

Actuate Therapeutics Inc.